BOSTON, Oct. 9, 2019 /PRNewswire/ -- Front Line Genomics
is excited to announce the first annual World Metastasis Summit,
taking place November 20th - 21st in
Boston, MA. The summit will bring
together industry experts across the field from academia and
industry, to collaborate on research and findings with the intent
of increasing the number of promising anti-metastasis therapies.
Understanding and tackling metastatic cancer is the single biggest
opportunity to improve outcomes for most cancer patients.
"We have had an incredible amount of support from the oncology
community in putting this event together," commented event founder,
Dr. Richard Lumb adding that "As a
result, our speaker line-up is unrivaled in terms of its breadth
and depth of experience and ideas, including world-renowned cancer
researchers, global pharma companies, emerging biotechs, tech
companies and innovative, young researchers."
Among the list of summit speakers are eminent cancer researchers
like Bob Weinberg from MIT, pharmaceutical researchers from AstraZeneca,
J&J, and Eisai, as well as established research scientists from
places like Stanford and Harvard. As far as attendees are concerned, this
multidisciplinary summit will draw cancer/metastasis researchers,
drug developers, clinicians, patient organization executives, and
technology leaders who want to be at the forefront of tackling
metastases therapeutically. This wide-spectrum of backgrounds will
contribute to the core strength of this event.
The World Metastasis Summit represents a huge opportunity to
improve the development of existing cancer drugs, reverse declining
clinical success rates in oncology, drive the development of new
therapies, and treat more aggressive cancers to improve survival
rates for metastatic cancers.
"This conference is a tremendous opportunity not only to hear
about the cutting edge of work in metastasis but an opportunity to
identify areas of synergy where new collaborations could be
fostered to accelerate the understanding of metastatic processes
and to develop new therapeutic interventions," said Andrew P. Mazar, Ph.D., Chief Scientific Officer
from Monopar Therapeutics, Inc.
With a commitment to cause, and a mindset of inclusivism, the
leaders of the World Summit have designed this event so that it is
not cost-prohibitive for anyone. All interested parties should read
more about the event here or contact Dr. Lumb directly at
richard@frontlinegenomics.com.
About Front Line Genomics
Motivated by personal tragedy, Dr. Richard Lumb founded Front Line Genomics in 2014
with the mission to help deliver the benefits of genomics faster.
Front Line Genomics is an organization that helps deliver the
benefits of genomics right to the 'front line' of healthcare as
quickly as possible with a strong focus on the potential of
translational genomics in both healthcare and society.
More than just an events and media business, Front Line Genomics
puts the genomics community, and indirectly, the patient, at the
very heart of its decision-making processes. With a focus on
accelerating the impact of genomic knowledge on people's lives,
they facilitate collaboration across scientists, clinicians,
business/research leaders and officials, from academia, research
institutes, industry, healthcare and organizations to realize the
true potential of genomic medicine.
Media Contact:
Jessica Tobey
Speaks Marketing Group
818-939-4121
Jessica@speaksmarketing.com
www.speaksmarketing.com
View original
content:http://www.prnewswire.com/news-releases/group-spearheads-event-to-drive-therapies-aimed-at-biggest-cause-of-cancer-deaths-300934844.html
SOURCE Front Line Genomics